Pharmaceuticals

As COVID revenues fall, BioNTech bets its future on a robust oncology pipeline. The upcoming Q1 2026 report will reveal the financial health of this pivot.

New preclinical data for InnoCare's ICP-B794 reveals a wider safety window and power to overcome drug resistance, positioning it as a top contender.

UK biotech Promatix presented a new AI-driven platform at AACR 2026 that finds thousands of new cancer targets, promising safer, more precise 'smart bomb' drugs.

ProRx Pharma touts a major expansion to meet drug demand, but recent FDA warnings and massive recalls raise serious questions about its quality and safety.

AI promises to transform drug discovery, but billions in investment are at risk. A new report reveals why the real bottleneck isn't tech, but data itself.

Harrington Discovery Institute opens its 2027 award call, offering millions in funding and expert support to turn academic research into life-saving medicines.

A novel drug candidate from Addex Therapeutics shows robust cough suppression in key preclinical studies, offering hope for a treatment without current side effects.

With a $719M war chest from its blockbuster IPO, Kailera Therapeutics is poised to challenge the dominance of Lilly and Novo in the lucrative obesity market.

A novel 'payload-bearing' drug shows potent preclinical activity against a rare pediatric cancer, paving an accelerated path to human trials.

Millions suffer from osteoporosis, but many refuse injections. Now, a biotech company's oral pill aims to bridge a massive treatment gap. Here's how.

Following a breakthrough in chondrosarcoma, Inhibrx Biosciences is set to reveal pivotal data for its drug ozekibart in the vast colorectal cancer market.

Freshly spun-off from AnaptysBio, First Tracks Biotherapeutics hits the market with a strong cash position and a pipeline aimed at celiac disease and RA.

ATCC and the Broad Institute unveil engineered lung cancer cells to decode drug resistance, offering new hope for patients and fueling AI-driven discovery.

Atsena Therapeutics gets the green light for the final trial phase of a promising gene therapy, offering the first real hope for patients with X-linked retinoschisis.

PeptiDream and Asahi Kasei's novel drug candidate, AK1940, begins Phase 1 trials, aiming for a safer, more targeted approach to treating autoimmune diseases.

Upcoming Phase 1 data for ABCL635 could validate a novel antibody approach for hot flashes, challenging the market and offering new hope for millions.

A breakthrough drug for pediatric Hunter syndrome, AVLAYAH™, is now accessible via home infusion through an exclusive Orsini and Denali partnership.

With Cigna's backing, Accord's IMULDOSA is set to challenge a blockbuster drug, promising significant savings for patients and the healthcare system.

A new alcohol-free, no-refrigeration blood pressure liquid aims to transform daily treatment for children, reflecting a key industry shift.

Astellas and Pfizer's PADCEV-Keytruda combo, showing a 47% drop in recurrence risk, earns FDA Priority Review, offering new hope for bladder cancer patients.